Business context and reporting period
The supplied filing is MRI Interventions, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2012; the filing does not identify Clearpoint Neuro, Inc. as the registrant. MRI Interventions developed and commercialized MRI-guided minimally invasive procedure systems. Its ClearPoint system was cleared for general neurological procedures and in commercial use; its ClearTrace cardiac system remained in development without regulatory clearance.
Financial performance and condition
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $1.084 million | $723,000 | $2.064 million | $1.499 million |
| Operating loss | $480,000 | $1.472 million | $1.631 million | $3.179 million |
| Net loss | $600,000 | $2.069 million | $4.074 million | $4.320 million |
| Operating cash flow | Not separately presented | Not separately presented | $(3.252) million | $(3.479) million |
Q2 revenue included $650,000 of related-party license revenue, $142,000 of development services, and $291,000 of product revenue. For the first half, those categories were $1.300 million, $251,000, and $513,000, respectively. Product gross margin was approximately 46% in Q2 2012 versus 58% in Q2 2011, and approximately 50% for the first half versus 43% in the prior-year period.
At June 30, cash and equivalents were $1.223 million, total assets $4.834 million, total liabilities $15.568 million, and stockholders’ deficit $10.734 million. Negative working capital was $6.206 million. Accounts payable was $2.845 million. Debt carrying values included $4.339 million owed to Boston Scientific, $2.000 million under the Brainlab convertible note, and $192,000 of junior secured notes; the latter amount is net of a $2.808 million unamortized discount. Financing provided $4.414 million in the first half, while investing used $85,000.
Material changes versus the prior comparable period
- Q2 revenue rose 50%, largely on higher ClearPoint product sales and new development-services revenue. First-half revenue increased 38%.
- First-half operating loss narrowed, but reported net loss improved only modestly. The comparison was affected by $883,000 of expense reversals in 2012 and $2.058 million of debt-cost and discount amortization/write-offs included in first-half interest expense.
- Research and development costs fell 47% for the first half, principally because sponsored research and ClearTrace development spending were reduced while the company sought financing.
- Selling, general and administrative expense rose 34% for the first half, including $572,000 of warrant compensation and higher public-company, legal, accounting, and investor-relations costs.
- In February 2012, $10.812 million of convertible-note principal and $974,000 of accrued interest converted into common shares. The company also converted its Series A preferred stock. These transactions reduced debt but substantially increased shares outstanding.
Outlook, risks, contingencies, and unusual items
Management said June-end resources plus the July 2012 financing and product sales were expected to fund anticipated cash needs through the first quarter of 2013. The company anticipated another equity or debt offering before then and warned that financing might not be available on acceptable terms. The July private placement raised $6.0 million gross, with approximately $5.520 million net proceeds; pro forma June 30 cash was approximately $5.753 million. The placement issued approximately 5.455 million common shares and warrants for approximately 2.727 million shares.
- The company had incurred substantial recurring losses and disclosed that its ability to continue as a going concern depended on additional financing and eventual revenue sufficient to cover costs.
- Boston Scientific’s $4.339 million secured notes were amended to 0% interest and maturities in late 2014. The related arrangement includes working-capital and other requirements; noncompliance could require assignment of specified intellectual property. Certain preferred-stock financings may also trigger mandatory prepayment.
- Under the Boston Scientific Neuro agreement, specified development milestones were due by December 31, 2012. Failure, absent lack of cooperation by Boston Scientific, could require repayment of amounts received; approximately $750,000 received was identified as subject to repayment.
- The $883,000 research and development credit reversed accrued service-based incentive obligations relinquished by participants. Separate sale-transaction bonuses remained: $1 million for each of two participants, plus a capped additional payment for one participant.
- Other principal risks include market adoption and reimbursement for ClearPoint, regulatory and development uncertainty for ClearTrace, reliance on collaborators and single-source suppliers, product quality and liability, and the company’s limited financing runway. The filing also warns of potential dilution and illiquidity in its OTC Bulletin Board shares.
Important facts for investors to verify
- Confirm the issuer identity: this filing names MRI Interventions, Inc., despite the request metadata naming Clearpoint Neuro, Inc.
- Verify cash runway against actual July financing proceeds, subsequent cash burn, and the company’s stated need for further financing by early 2013.
- Track ClearPoint procedure volumes, product revenue mix, and product gross margins; confirm whether growth is recurring and independent of development-services revenue.
- Check progress against Boston Scientific Neuro’s December 2012 milestones and any resulting repayment exposure or intellectual-property consequences.
- Assess dilution from the July share-and-warrant financing and the potential conversion or exercise of outstanding securities.